These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27795368)

  • 1. Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults.
    Yu XQ; Robbie GJ; Wu Y; Esser MT; Jensen K; Schwartz HI; Bellamy T; Hernandez-Illas M; Jafri HS
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcus aureus Disease.
    Tkaczyk C; Hamilton MM; Sadowska A; Shi Y; Chang CS; Chowdhury P; Buonapane R; Xiao X; Warrener P; Mediavilla J; Kreiswirth B; Suzich J; Stover CK; Sellman BR
    mBio; 2016 Jun; 7(3):. PubMed ID: 27353753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting
    Magyarics Z; Leslie F; Bartko J; Rouha H; Luperchio S; Schörgenhofer C; Schwameis M; Derhaschnig U; Lagler H; Stiebellehner L; Firbas C; Weber S; Campanaro E; Jilma B; Nagy E; Stevens C
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31138568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
    Gaudinski MR; Coates EE; Houser KV; Chen GL; Yamshchikov G; Saunders JG; Holman LA; Gordon I; Plummer S; Hendel CS; Conan-Cibotti M; Lorenzo MG; Sitar S; Carlton K; Laurencot C; Bailer RT; Narpala S; McDermott AB; Namboodiri AM; Pandey JP; Schwartz RM; Hu Z; Koup RA; Capparelli E; Graham BS; Mascola JR; Ledgerwood JE;
    PLoS Med; 2018 Jan; 15(1):e1002493. PubMed ID: 29364886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alanine Scanning Mutagenesis of the MEDI4893 (Suvratoxumab) Epitope Reduces Alpha Toxin Lytic Activity
    Tkaczyk C; Semenova E; Shi YY; Rosenthal K; Oganesyan V; Warrener P; Stover CK; Sellman BR
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Staphylococcus aureus Alpha-Toxin Is Conserved among Diverse Hospital Respiratory Isolates Collected from a Global Surveillance Study and Is Neutralized by Monoclonal Antibody MEDI4893.
    Tabor DE; Yu L; Mok H; Tkaczyk C; Sellman BR; Wu Y; Oganesyan V; Slidel T; Jafri H; McCarthy M; Bradford P; Esser MT
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5312-21. PubMed ID: 27324766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of alpha-toxin hla gene variants, alpha-toxin expression levels, and levels of antibody to alpha-toxin in hemodialysis and postsurgical patients with Staphylococcus aureus bacteremia.
    Sharma-Kuinkel BK; Wu Y; Tabor DE; Mok H; Sellman BR; Jenkins A; Yu L; Jafri HS; Rude TH; Ruffin F; Schell WA; Park LP; Yan Q; Thaden JT; Messina JA; Fowler VG; Esser MT
    J Clin Microbiol; 2015 Jan; 53(1):227-36. PubMed ID: 25392350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multimechanistic Monoclonal Antibodies (MAbs) Targeting Staphylococcus aureus Alpha-Toxin and Clumping Factor A: Activity and Efficacy Comparisons of a MAb Combination and an Engineered Bispecific Antibody Approach.
    Tkaczyk C; Kasturirangan S; Minola A; Jones-Nelson O; Gunter V; Shi YY; Rosenthal K; Aleti V; Semenova E; Warrener P; Tabor D; Stover CK; Corti D; Rainey G; Sellman BR
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study.
    Sivapalasingam S; Kamal M; Slim R; Hosain R; Shao W; Stoltz R; Yen J; Pologe LG; Cao Y; Partridge M; Sumner G; Lipsich L
    Lancet Infect Dis; 2018 Aug; 18(8):884-893. PubMed ID: 29929783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation of anti-alpha toxin antibody levels and colonisation status after administration of an investigational human monoclonal antibody, MEDI4893, against
    Ruzin A; Wu Y; Yu L; Yu XQ; Tabor DE; Mok H; Tkaczyk C; Jensen K; Bellamy T; Roskos L; Esser MT; Jafri HS
    Clin Transl Immunology; 2018; 7(1):e1009. PubMed ID: 29484186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia.
    Gunale B; Farinola N; Kamat CD; Poonawalla CS; Pisal SS; Dhere RM; Miller C; Kulkarni PS
    Lancet Infect Dis; 2024 Jun; 24(6):639-649. PubMed ID: 38408457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults.
    Robbie GJ; Criste R; Dall'acqua WF; Jensen K; Patel NK; Losonsky GA; Griffin MP
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6147-53. PubMed ID: 24080653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti-
    Peck M; Rothenberg ME; Deng R; Lewin-Koh N; She G; Kamath AV; Carrasco-Triguero M; Saad O; Castro A; Teufel L; Dickerson DS; Leonardelli M; Tavel JA
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910894
    [No Abstract]   [Full Text] [Related]  

  • 14. Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers.
    Lim JJ; Deng R; Derby MA; Larouche R; Horn P; Anderson M; Maia M; Carrier S; Pelletier I; Burgess T; Kulkarni P; Newton E; Tavel JA
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5437-44. PubMed ID: 27381392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults.
    Weisman LE; Fischer GW; Thackray HM; Johnson KE; Schuman RF; Mandy GT; Stratton BE; Adams KM; Kramer WG; Mond JJ
    Int Immunopharmacol; 2009 May; 9(5):639-44. PubMed ID: 19268719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model.
    Hua L; Cohen TS; Shi Y; Datta V; Hilliard JJ; Tkaczyk C; Suzich J; Stover CK; Sellman BR
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4526-32. PubMed ID: 25987629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults.
    Ali SO; Yu XQ; Robbie GJ; Wu Y; Shoemaker K; Yu L; DiGiandomenico A; Keller AE; Anude C; Hernandez-Illas M; Bellamy T; Falloon J; Dubovsky F; Jafri HS
    Clin Microbiol Infect; 2019 May; 25(5):629.e1-629.e6. PubMed ID: 30107283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial.
    François B; Mercier E; Gonzalez C; Asehnoune K; Nseir S; Fiancette M; Desachy A; Plantefève G; Meziani F; de Lame PA; Laterre PF;
    Intensive Care Med; 2018 Nov; 44(11):1787-1796. PubMed ID: 30343314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Alpha Toxin To Mitigate Its Lethal Toxicity in Ferret and Rabbit Models of Staphylococcus aureus Necrotizing Pneumonia.
    Diep BA; Hilliard JJ; Le VT; Tkaczyk C; Le HN; Tran VG; Rao RL; Dip EC; Pereira-Franchi EP; Cha P; Jacobson S; Broome R; Cheng LI; Weiss W; Prokai L; Nguyen V; Stover CK; Sellman BR
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of IgG and Neutralizing Antibodies against Staphylococcus aureus Alpha-Toxin in Healthy Human Subjects and Diverse Patient Populations.
    Wu Y; Liu X; Akhgar A; Li JJ; Mok H; Sellman BR; Yu L; Roskos LK; Esser MT; Ruzin A
    Infect Immun; 2018 Mar; 86(3):. PubMed ID: 29263109
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.